Interleukin-15 modulates interferon-γ and β-chemokine production in patients with HIV infection: Implications for immune-based therapy

Cytokine

Volumn 25, Issue 6, 2004, Pages 283-290

  Forcina, Gabriele ^a   D'Ettorre, Gabriella ^a   Mastroianni, Claudio M ^a   Carnevalini, Martina ^a   Scorzolini, Laura ^a   Ceccarelli, Giancarlo ^a   D'Agostino, Claudia ^a   Lichtner, Miriam ^a   Massetti, Anna P ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HAART; HIV; Interferon ; Interleukin 15; Chemokines

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL PROTEIN; BETA CHEMOKINE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; RECOMBINANT INTERLEUKIN 15;

ADULT; ANTIGEN PURIFICATION; ARTICLE; BLOOD CELL; BLOOD DONOR; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG RESPONSE; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; MALE; MONOCYTE; MYCOBACTERIUM AVIUM; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; T LYMPHOCYTE; TREATMENT FAILURE;

MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX;

EID: 10744233141     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2003.12.004     Document Type: Article

References (32)

1. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 337:1997;734-739.
2. Markowitz M., Vesanen M., Tenner-Racz K., Cao Y., Binley J.M., Talal A., et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 179:1999;527-537.
3. Lederman M.M., Valdez H. Immune restoration with antiretroviral therapies. J Am Med Assoc. 284:2000;223-228.
4. Allende M.C., Lane H.C. Cytokine-based therapies for HIV infection. AIDS. 15:2001;S183-S191.
5. Carson W., Caligiuri M.A. Interleukin-15 as potential regulator of the innate immune response. Brazil J Med Biol Res. 31:1998;1-9.
6. Waldmann T.A., Tagaya Y. The multifaceted regulation of interleukin-15 and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 17:1999;19-49.
7. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., et al. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:1994;2822-2830.
8. Giri J.G., Kumaki S., Ahdieh M., Friend D.J., Loomis A., Shanebeck K., et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14:1995;3654-3663.
9. Grabstein K.H., Eisenmann J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T-cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:1994;965-968.
10. Kanai T., Thomas E.K., Yasutomi Y., Letvin N.L. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol. 157:1996;3681-3687.
11. Perera L.P., Goldman C.K., Waldmann T.A. IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J Immunol. 162:1999;2606-2612.
12. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood. 97:2001;14-32.
13. Chehimi J., Marshall J.D., Salvucci O., Frank I., Chehimi S., Kawecki S., et al. IL-15 enhances immune functions during HIV infection. J Immunol. 158:1997;5978-5987.
14. Seder R.A., Grabstein K.H., Berzofsky J.A., McDyer J.F. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med. 182:1995;1067-1077.
15. Patki A.H., Quinones-Mateu M.E., Dorazio D., Yen-lieberman B., Boom W.H., Thomas E.K., et al. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression. J Clin Invest. 98:1996;616-621.
16. Lin S.J., Roberts R.L., Ank B.J., Nguyen Q.H., Thomas E.K., Stiehm E.R. Human immunodeficiency virus(HIV) type-1 gp120-specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2(IL-2), IL-12, and IL-15. Clin Immunol Immunopathol. 82:1997;163-173.
17. Mastroianni C.M., d'Ettorre G., Forcina G., Lichtner M., Mengoni F., D'Agostino C., et al. Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. Blood. 96:2000;1979-1984.
18. d'Ettorre G., Forcina G., Lichtner M., Mengoni F., D'Agostino C., Massetti A.P., et al. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naïve and -treated patients. AIDS. 16:2002;181-188.
19. Chougnet C., Shearer G.M., Landay A.L. The role of antigen-presenting cells in HIV pathogenesis. Curr Infect Dis Rep. 4:2002;266-271.
20. Crowe S.M., Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol. 68:2000;345-350.
21. Zhu T., Muthui D., Holte S., Nickle D., Feng F., Brodie S., et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol. 76:2002;707-716.
22. Meyaard L., Hovenkamp E., Keet I.P., Hooibrink B., de Jong I.H., Otto S.A., et al. Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J Immunol. 157:1996;2712-2718.
23. Barcellini W., Rizzardi G.P., Borghi M.O., Fain C., Lazzarin A., Meroni P.L. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS. 8:1994;757-762.
24. Cocchi F., De Vico A., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1995;1811-1815.
25. Esser R., Glienke W., Andreesen R., Unger R.E., Kreutz M., Rubsamen-Waigmann H., et al. Individual cell analysis of the cytokine repertoire in human immunodeficiency virus-1-infected monocytes/macrophages by a combination of immunochemistry and in situ hybridisation. Blood. 91:1998;4752-4760.
26. Meyard L., Hovenkamp E., Keet I.P., Hooibrink B., de Jong I.H., Oho S.A., et al. Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J Immunol. 157:1996;2712-2718.
27. + T cells. Blood. 101:2003;1024-1029.
28. Fransen S., Copeland K.F.T., Smieja M., Smaill F., Rosenthal K.L. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication. J Infect Dis. 181:2000;505-512.
29. Hofman B., Jakobsen R., Odum N., Dickmeiss E., Platz P., Ryder L.P., et al. Relatively preserved phytohemagglutinin as opposed to decreased pokeweed mitogen responses may be due to possibly preserved responses via CD2/phytohemagglutinin pathway. J Immunol. 142:1989;1874-1880.
30. Mackewicz C.E., Barker E., Greco G., Reyes-Teran G., Levy J.A. Do β-chemokines have clinical relevance in HIV infection? J Clin Invest. 100:1997;921-930.
31. Kaufmann G.R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A., et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 163:2003;2187-2195.
32. Oliva A., Kinter A.L., Vaccarezza M., Rubbert A., Catanzaro A., Moir S., et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 102:1998;223-231.